AbbVie scores surprisingly good Q2 results but pipeline worries persist
admin 28th July 2017 Uncategorised 0July has been a tough month for AbbVie, marked by a stinging patent loss on its megablockbuster Humira and a negative verdict in the first bellwether case against its once-blockbuster testosterone drug AndroGel. Even the better-than-expected earnings announced today created some concerns among investors.
More: AbbVie scores surprisingly good Q2 results but pipeline worries persist
Source: fierce